The structure of unknown compounds present in herbal products was elucidated using liquid chromatography-electrospray ionization-mass spectrometry, direct-infusion electrospray ionization-mass spectrometry, and nuclear magnetic resonance. Compounds 1-3 were identified as sildenafil analogues, 1 bearing an N-ethylpiperazine moiety instead of an Nmethylpiperazine, and an acetyl group instead of the sulfonyl group, named acetildenafil, 2 bearing an N-ethylpiperazine moiety instead of an N-methylpiperazine (homosildenafil), and 3 bearing an N-hydroxylethylpiperazine moiety instead of an N-methylpiperazine, named hydroxyhomosildenafil. When analysing products marketed for penile erectile dysfunction or marketed as aphrodisiacs, attention should be given to the possible presence of these components.
Introduction
Sildenafil is the active compound in Viagra®, a prescription medicine for penile erectile dysfunction. However, it is also found in aphrodisiacs, mainly advertised as natural products. As aphrodisiacs and natural products increase in popularity, especially via the World Wide Web, this will be a global problem: consumers are not aware of taking a prescription drug that has contraindications.
Recently, the present authors identified three sildenafil analogues in three different herbal products. A completely new analogue 1, named acetildenafil, was identified in product A, oral capsules, advertised as 'a firm erection of Mother Nature', based on traditional Chinese medicine. Homosildenafil (2) was identified in product B, Chinese oral tablets, labelled as a herbal preparation containing Juglans regia (walnut), to be used as an anti-fatigue agent according to the package leaflet. However, it was sold as herbal Viagra. Shin et al. (2003) published the structure of this analogue using nuclear magnetic resonance (NMR) spectroscopy. The compound was discovered in a beverage marketed for erectile dysfunction. Hydroxyhomosildenafil (3) was identified in product C, Chinese oral capsules, advertised as an herbal alternative for Viagra.
Based on the structural analogy of these three compounds with sildenafil, similar biological activity is to be expected. Pfizer (unpublished data) reported limited pharmacological data for hydroxyhomosildenafil, demonstrating biological activity comparable with sildenafil. In Japan, one case of liver function impairment was reported that might be due to the use of a product containing hydroxyhomosildenafil (Japan, Pharmaceutical and Food Safety Bureau -Health, Labor, and Welfare Ministry 2004). Beside this limited information, no data on toxicology and efficacy are described in the public (medical) literature for these three analogues. It seems there is a tendency towards the development of designer drugs based on sildenafil that might present a risk for human health. This paper describes the elucidation of these three compounds using liquid chromatographyelectrospray ionization-mass spectrometry (LC-ESI-MS n ), direct-infusion ESI-MS n , and 1 Hand 13 C-NMR.
Materials and methods

Samples
Product A and C were submitted by the Dutch Food and Consumer Product Safety Authority for analysis on phosphodiesterase type 5 enzyme (PDE5) inhibitors. Product B was submitted by the Dutch Health Care Inspectorate for analysis on sildenafil. . The working solution was prepared by diluting the stock solution with mobile phase to about 6.5 µg ml -1 sildenafil. Tablets of Cialis® were ground, tablet powder was dissolved in MeOH and diluted with mobile phase to about 2 µg ml -1 tadalafil. Similarly, a solution of about 2 µg ml -1 vardenafil was prepared from tablets of Levitra®.
Materials for LC-ESI-MS n and direct-infusion ESI-MS
Sample A
For direct-infusion ESI-MS n , the content of four capsules was homogenized and approximately 380 mg were dissolved in 100 ml MeOH by sonification. After filtration over a 0.45-µm filter, the solution was diluted 1:10 with mobile phase. This solution was also diluted 1:10 with mobile phase for LC-MS n analysis. For NMR analysis, the compound of interest was isolated by dissolving the content of one capsule, approximately 100 mg, in 1 ml DMSO : water (20:80 v/v). The product was isolated by reversed-phase liquid chromatography on C 18 material, washing with 10 ml water, followed by 10-ml mixtures of methanol and water with increasing amounts of methanol (v/v 10, 40, 60 and 90%). The compound was eluted from the column with 10 ml ACN:0.5 M HCl (10:90 v/v). The fractions containing the product were pooled and evaporated to dryness under a stream of nitrogen. The residue was dissolved in 2 ml water, basified using 1 M NaOH solution and extracted with CHCl 3 . The organic layer was washed with water, dried over Na 2 SO 4 and evaporated yielding a white solid. The solid was dissolved in CDCl 3 for NMR analysis. For IR analysis, the solvent was evaporated and the residue prepared as for the KBr tablet.
Sample B
For LC-MS n analysis, one tablet was ground and about 50 mg were dissolved in 25 ml MeOH by sonification. After filtration over a 0.45-µm filter, the solution was diluted 1:200 with mobile phase. For NMR analysis, the compound of interest was isolated by extracting one ground tablet three times with 5 ml acetone followed by three times with 5 ml water. The water layer was basified using 5 M NaOH solution and extracted three times with 10 ml CHCl 3 . The organic layers were combined, dried with Na 2 SO 4 , filtered and evaporated to dryness under a stream of nitrogen. The residue was dissolved in approximately 0.8 ml CDCl 3 .
Sample C
For direct-infusion ESI-MS n , the content of three capsules was homogenized and approximately 210 mg were dissolved in 50 ml MeOH by sonification. After filtration over a 0.45-µm filter, the solution was diluted 1:10 with mobile phase. This solution was also diluted 1:10 with mobile phase for LC-MS n analysis. For qualitative NMR analysis, the compound of interest was isolated by extraction of 500 mg sample using acetone and water, and acid/base separation as described for sample A. For quantitative NMR analysis, 25 mg were dissolved in 0.7 ml D 2 O containing 0.075% TMSP as internal standard and 0.7 ml acetone-d 6 .
LC-ESI-MS n and direct-infusion ESI-MS n
For chromatographic separation and ultraviolet light detection, the following conditions were used: XTerra MS® C 18 guard column (20 × 2.1 mm, 3.5 µm) and XTerra MS® C 18 analytical column (100 × 2.1 mm, 3.5 µm; Waters Chromatography B.V., Etten-Leur, The Netherlands): isocratic elution using MeOH : acidified water (50:50 v/v); flow rate at 0.25 ml min : relevant ions selected and fragmented using a collision energy of 40.00 arbitrary units. Instrument conditions were checked using sildenafil citrate standard working solution. Samples A and C were analysed for PDE5 inhibitors; sample B was analysed for sildenafil only, using a standard analytical method (Bakker et al. 2004 ).
NMR spectra were recorded using standard single and multipulse sequences for one-and two-dimensional NMR spectra. FIDs were zero-filled, apodized using exponential (single pulse) or sinebell (multipulse) functions, phase and baseline corrected, and scaled against the residual CHCl 3 signal at 7.26 ( 1 H) or 77.0 ppm ( 13 C).
IR measurements were carried out over the spectral range 4000-400 cm -1 with an optical resolution of 2 cm -1 , and 32 scans were co-added.
Results and discussion
Sample A, compound 1
Based on LC-ESI-MS
n , direct-infusion ESI-MS n , 1 H-and 13 C-NMR, and IR data, the compound was identified as a sildenafil analogue bearing an N-ethylpiperazine moiety in stead of an N-methylpiperazine, and an acetyl group instead of the sulfonyl group (figure 1). Figure 1 . Structures of sildenafil (1) and analogues homosildenafil (2) and hydroxyhomosildenafil (3) . Structures: sildenafil (1) , (1-[[3-(6,7- (1) , (1-[[3-(6,7- 
dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]-acetyl]-4-ethylpiperazine) R=CH 3 .
Sample A was analysed for PDE5 inhibitors. Although sildenafil, vardenafil and tadalafil are absent, an abundant peak at a retention time of 0.8 relative to sildenafil is observed as well in the total scan chromatogram of the PDA as in the total ion current (TIC) chromatogram of the MS detector. The UV spectrum is very different from sildenafil, vardenafil and tadalafil (table  1) + of both 1 and sildenafil, but the relative intensities are less than 5% for both ions in 1 compared with 100 respectively 60% in sildenafil ( figure 2a, b) . + of sildenafil; however, an ion at m/z = 489 is present. Although this corresponds to the molecular mass of vardenafil, the active substance of Levitra, a relatively new medicine for erectile dysfunction, its retention behaviour on this chromatographic system and ultraviolet light spectrum are different (Bakker et al. 2004) . Based on the PDA total scan chromatogram and the assumption that the extinction coefficient of sildenafil and homosildenafil are comparable, the amount of homosildenafil in sample B was estimated at 142 mg/tablet.
Sample C, compound 3
Based on LC-ESI-MS n , direct-infusion ESI-MS n , and 1 H-and 13 C-NMR data, the compound was identified as a sildenafil analogue bearing an N-hydroxylethylpiperazine moiety instead of an N-methylpiperazine (figure 1).
Sample C was analysed for PDE5 inhibitors. An abundant peak is observed with a retention time and ultraviolet light spectrum comparable with sildenafil. In de MS Quantitative NMR analysis showed that sample C contained approximately 10% (w/w) hydroxyhomosildenafil, which corresponds to 45 mg/capsule.
As three different sildenafil analogues were identified over a short period, it seems there is a tendency towards designer drugs for Viagra counterfeits and herbal aphrodisiacs being distributed on the market. When analysing these products, attention should be given to the possible presence of this type of components. Only screening for the active ingredients of prescription drugs such as sildenafil and vardenafil is not sufficient anymore.
